9 active not recruiting. 9 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Active not recruiting 9 |
| Phase 1 | 6 | Active not recruiting 6 |
Follow Bronchiolitis: new trials by email Literature Review of Bronchiolitis trials Research Report on Bronchiolitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD INCA034176 - Chronic Graft-versus-host-disease | Phase 1 / Phase 2 | Active not recruiting | Incyte Corporation | 32 | 2025-06-25 | 2026-08-10 |
| A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease Axatilimab, Ruxolitinib, Corticosteroids - Chronic Graft-versus-host-disease | Phase 2 | Active not recruiting | Incyte Corporation | 130 | 2024-10-11 | 2026-10-15 |
| TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD)) TDI01 suspension - GVHD, Chronic | Phase 1 / Phase 2 | Active not recruiting | Beijing Tide Pharmaceutical Co., Ltd | 60 | 2024-02-06 | 2025-09-26 |
| Intracerebral Transplantation of Autologous MSC Combined With Scaffold Product for Chronic Intracerebral Hemorrhage HUFF-01 - Intracerebral Hemorrhage | Phase 1 / Phase 2 | Active not recruiting | Hokkaido University Hospital | 8 | 2023-12-01 | 2026-10-15 |
| A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease TQ05105 Tablet - Chronic Graft Versus Host Disease | Phase 1 / Phase 2 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 45 | 2021-06-25 | 2025-12-03 |
| ATG Plus PTCy vs ATG for CGVHD Prophylaxis Cyclophosphamide, Anti-Thymocyte globulin (rabbit) - Acute Leukemia, Myelodysplasia | Phase 2 | Active not recruiting | McMaster University | 80 | 2020-10-14 | 2025-05-11 |
| Wound Healing Endpoint and Recurrence Epiceram Skin Barrier Function, Vaseline Petroleum Jelly - Chronic Wound, Burn Wound | Phase 1 / Phase 2 | Active not recruiting | Sashwati Roy | 100 | 2019-01-08 | 2025-09-26 |
| Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation MPH966 - Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2016-04-28 | 2026-10-16 |
| Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease Interleukin-2 - Chronic Graft-versus-host Disease | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 35 | 2011-07-01 | 2026-02-20 |
Bronchiolitis Obliterans Syndrome (9) · Anemia, Refractory, with Excess of Blasts (1) · Burns (1) · Cerebral Hemorrhage (1) · Diabetic Foot (1) · Pressure Ulcer (1) · Wounds and Injuries (1)
Bronchial Diseases (9) · Bronchiolitis Obliterans (9) · Bronchitis (9) · Graft vs Host Disease (9) · Immune System Diseases (9) · Lung Diseases (9) · Lung Diseases, Obstructive (9) · Organizing Pneumonia (9) · Respiratory Tract Diseases (9) · Cardiovascular Diseases (2) · Vascular Diseases (2) · Anemia (1) · Anemia, Refractory (1) · Bone Marrow Diseases (1)
axatilimab (2) · Adrenal Cortex Hormones (1) · Antilymphocyte Serum (1) · Cyclophosphamide (1) · Interleukin-2 (1) · Methylprednisolone (1) · Petroleum (1) · Prednisolone (1) · Prednisone (1) · ruxolitinib (1) · thymoglobulin (1)
Incyte Corporation (2) · Beijing Tide Pharmaceutical Co., Ltd (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Dana-Farber Cancer Institute (1) · Hokkaido University Hospital (1) · McMaster University (1) · National Cancer Institute (NCI) (1) · Sashwati Roy (1)
United States (4) · China (3) · Canada (2) · Australia (1) · Belgium (1) · Germany (1) · Italy (1) · Japan (1) · Spain (1) · United Kingdom (1)
Irwin R Walker, MBBS (1) · John Koreth, MBBS, DPhil (1) · Kristjan Paulson, MD (1) · Najla El Jurdi, M.D. (1) · Sashwati Roy, PhD (1)
PMID 34398099, PMID 40009501, PMID 42629427
P01CA142106 (1)